PE20040765A1 - 4-amino piperidinas n,n-disustituidas como inhibidores de la captacion de monoamina - Google Patents

4-amino piperidinas n,n-disustituidas como inhibidores de la captacion de monoamina

Info

Publication number
PE20040765A1
PE20040765A1 PE2003001225A PE2003001225A PE20040765A1 PE 20040765 A1 PE20040765 A1 PE 20040765A1 PE 2003001225 A PE2003001225 A PE 2003001225A PE 2003001225 A PE2003001225 A PE 2003001225A PE 20040765 A1 PE20040765 A1 PE 20040765A1
Authority
PE
Peru
Prior art keywords
alkyl
halogen
inhibitors
cyane
methylpropyl
Prior art date
Application number
PE2003001225A
Other languages
English (en)
Inventor
Manuel Javier Cases-Thomas
Barry Peter Clark
Peter Thaddeus Gallagher
Virginia Ann Wood
John Joseph Masters
Graham Henry Timms
Maria Ann Whatton
Jeremy Gilmore
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0228482A external-priority patent/GB0228482D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20040765A1 publication Critical patent/PE20040765A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA I, DONDE n ES 1, 2 O 3; R1 ES ALQUILO(C2-C10), ALQUENILO(C2-C10), CICLOALQUILO(C3-C8) O CICLOALQUIL(C4-C10)-ALQUILO, DONDE UN ENLACE C-C DEL CICLOALQUIL ESTA SUSTITUIDO POR UN ENLACE C-O, S-C o C=C, Y OPCIONALMENTE SUSTITUIDO POR 1 A 7 SUSTITUYENTES DE HALOGENO Y/O CON 1 A 3 HIDROXI, CIANO, ALQUILO(C1-C4), ENTRE OTROS; R2, R3 Y R4 SON H, ALQUILO(C1-C4), ALQUILO(C1-C4)-S(O)x DONDE x ES 0, 1 O 2, ALCOXI(C1-C4) (OPCIONALMENTE SUSTITUIDO CON 1 A 7 HALOGENOS), CIANO, HALOGENO, ENTRE OTROS; O R2 Y R3 O R3 Y R4, JUNTOS FORMAN UN ANILLO DE BENCENO ADICIONAL (OPCIONALMENTE SUSTITUIDO POR 1 A 3 HALOGENOS, ALQUILO(C1-C4) O ALCOXI(C1-C4); R5 Y R6 SON H, HALOGENO, ALQUILO(C1-C4), ALCOXI(C1-C4) (OPCIONALMENTE SUSTITUIDOS CON 1 A 7 HALOGENOS); R7 Y R8 SON H O ALQUILO(C1-C4); R9 Y R10 SON H, HALOGENO, HIDROXI, CIANO, ALQUILO C1-C4 O ALCOXI(C1-C4). SON COMPUESTOS PREFERIDOS: N-(1-METILETIL)-N-{[2-(TRIFLUOROMETIL)FENIL]METIL}PIPERIDIN-4-AMINA, N-(2-METILPROPIL)-N-{[4-(METOXI)FENIL]METIL}PIPERIDIN-4-AMINA, N-(2-METILPROPIL)-N-{[4-(CLORO)FENIL]METIL}PIPERIDIN-4-AMINA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA SU PRODUCCION Y UNA FORMA FARMACEUTICA QUE LO CONTIENE. ESTOS COMPUESTOS SON INHIBIDORES DE LA CAPTACION DE SEROTONINA Y/O NOREPINEFRINA Y/O DOPAMINA Y SON UTILES PARA EL TRATAMIENTO DE TRANSTORNOS DEL SISTEMA NERVIOSO CENTRAL O PERIFERICO
PE2003001225A 2002-12-06 2003-12-02 4-amino piperidinas n,n-disustituidas como inhibidores de la captacion de monoamina PE20040765A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0228482A GB0228482D0 (en) 2002-12-06 2002-12-06 Inhibitors of monoamine uptake
US43472002P 2002-12-18 2002-12-18

Publications (1)

Publication Number Publication Date
PE20040765A1 true PE20040765A1 (es) 2004-12-02

Family

ID=32510397

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003001225A PE20040765A1 (es) 2002-12-06 2003-12-02 4-amino piperidinas n,n-disustituidas como inhibidores de la captacion de monoamina

Country Status (6)

Country Link
US (1) US20060079554A1 (es)
EP (1) EP1569905A2 (es)
AR (1) AR042284A1 (es)
AU (1) AU2003290735A1 (es)
PE (1) PE20040765A1 (es)
WO (1) WO2004052858A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE383335T1 (de) * 2003-06-11 2008-01-15 Lilly Co Eli 3-amino-pyrrolidine als inhibitoren der monoamin- wiederaufnahme
WO2005053663A2 (en) * 2003-11-24 2005-06-16 Eli Lilly And Company Norepinephrine reuptake inhibitors useful for treatment of cognitive failure
JP2007513945A (ja) * 2003-12-12 2007-05-31 イーライ リリー アンド カンパニー 体熱感、衝動調節障害および一般的な病状による人格変化の治療
EP1735302B1 (en) 2004-02-27 2010-06-16 Eli Lilly And Company 4-amino-piperidine derivatives as monoamine uptake inhibitors
EP1756050A1 (en) * 2004-06-01 2007-02-28 Eli Lilly And Company Aminomethyl-azacycle derivatives as inhibitors of monoamine uptake
WO2007003962A2 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
WO2007041494A2 (en) * 2005-09-30 2007-04-12 Merck & Co., Inc. Cholesteryl ester transfer protein inhibitors
CN101432261A (zh) 2006-05-19 2009-05-13 惠氏公司 作为组织胺-3拮抗剂的n-苯甲酰基-吡咯烷-3-基胺和n-苄基-吡咯烷-3-基胺
UA112897C2 (uk) 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
EP3066098A1 (de) 2013-11-08 2016-09-14 Bayer Pharma Aktiengesellschaft Substituierte uracile und ihre verwendung
WO2016146607A1 (de) 2015-03-18 2016-09-22 Bayer Pharma Aktiengesellschaft Verfahren zur herstellung von (4s)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluormethyl)phenyl]-1,2,3,4-tetrahydro pyrimidin-5-carbonitril
WO2018045376A2 (en) * 2016-09-02 2018-03-08 Ikaria Inc. Functionally modified polypeptides and radiobiosynthesis
CN110256285B (zh) * 2019-07-09 2022-03-18 上海出入境检验检疫局动植物与食品检验检疫技术中心 一种稳定同位素标记拟除虫菊酯的合成方法
WO2024105007A1 (en) * 2022-11-15 2024-05-23 Samsara Therapeutics Inc. Autophagy inducing compounds and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0026469B1 (en) * 1979-10-01 1984-11-28 Sandoz Ag Dibenzazepine derivatives, their production and pharmaceutical compositions containing them
US4886809A (en) * 1986-07-31 1989-12-12 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof
US5567718A (en) * 1994-08-11 1996-10-22 Hoechst Marion Roussel Inc. 2,3-dihydro-1h-isoindole derivatives and their use as serotonin reuptake inhibitors
US7488741B2 (en) * 2002-10-04 2009-02-10 Ucb Pharma, S.A. 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments

Also Published As

Publication number Publication date
AU2003290735A8 (en) 2004-06-30
AR042284A1 (es) 2005-06-15
US20060079554A1 (en) 2006-04-13
WO2004052858A3 (en) 2004-08-12
EP1569905A2 (en) 2005-09-07
AU2003290735A1 (en) 2004-06-30
WO2004052858A2 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
PE20040765A1 (es) 4-amino piperidinas n,n-disustituidas como inhibidores de la captacion de monoamina
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
PE20070491A1 (es) Compuestos derivados de 9-azabiciclo[3.3.1]nonano como inhibidores de la recaptacion de neurotransmisores de monoamina
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
PE20050874A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
NI200700270A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
PE20070519A1 (es) Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c
UY26872A1 (es) Derivados de la 4- fenil piridina
AR056103A1 (es) Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
PE20020063A1 (es) Bis-arilsulfonas como ligandos del receptor de 5-ht
PE20050132A1 (es) Piperazinas heterociclicas sustituidas
PE20010522A1 (es) Aminoalcoxicarbazoles como antagonistas de los receptores 5ht
PE20030610A1 (es) Derivados de 3-azabiciclo[3.1.0]hexano con afinidad a los receptores opioides
PE20060632A1 (es) Derivados de arilsulfonilestilbeno como antagonistas de los receptores 5-ht2a
PE20081152A1 (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3
PE20081504A1 (es) Compuestos de biciclocarboxiamida sustituidos
ECSP066415A (es) 2-carbonilamino-6-piperidinaminopiridinas sustituidas y 1-carbonilamino-3-piperidinaminobenzenos sustituidos como 5-ht1f agonistas
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20000467A1 (es) Derivado de indol util como inhibidor de serotonina
CL2012000516A1 (es) Compuestos derivados de 3-[4-(4-(fenil/piridin/ pirimidin)- piperazin -1-il)-butil]-2, 3-dihidro-4h-croman-4-ona, moduladores del receptor de dopamina d3; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de un desorden neurologico o psiquiatrico, disfuncion erectil o dependencia a drogas, entre otros.
AR074466A1 (es) Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal